<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p182" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_182{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_182{left:306px;bottom:30px;}
#t3_182{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_182{left:346px;bottom:30px;}
#t5_182{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_182{left:517px;bottom:30px;}
#t7_182{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_182{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_182{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_182{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_182{left:35px;bottom:777px;letter-spacing:0.09px;word-spacing:-0.83px;}
#tc_182{left:35px;bottom:754px;letter-spacing:0.04px;word-spacing:-0.34px;}
#td_182{left:285px;bottom:754px;letter-spacing:0.18px;word-spacing:0.01px;}
#te_182{left:35px;bottom:731px;letter-spacing:0.2px;word-spacing:-0.01px;}
#tf_182{left:416px;bottom:731px;letter-spacing:0.07px;word-spacing:0.11px;}
#tg_182{left:35px;bottom:707px;letter-spacing:0.19px;}
#th_182{left:35px;bottom:667px;letter-spacing:0.11px;word-spacing:0.08px;}
#ti_182{left:35px;bottom:645px;letter-spacing:0.11px;word-spacing:0.08px;}
#tj_182{left:35px;bottom:622px;letter-spacing:0.08px;word-spacing:0.1px;}
#tk_182{left:35px;bottom:599px;letter-spacing:0.1px;word-spacing:0.09px;}
#tl_182{left:35px;bottom:575px;letter-spacing:0.07px;word-spacing:0.12px;}
#tm_182{left:35px;bottom:552px;letter-spacing:0.12px;word-spacing:-0.08px;}
#tn_182{left:488px;bottom:560px;letter-spacing:0.1px;}
#to_182{left:533px;bottom:552px;letter-spacing:0.35px;word-spacing:-0.17px;}
#tp_182{left:35px;bottom:529px;letter-spacing:0.12px;word-spacing:-0.28px;}
#tq_182{left:35px;bottom:506px;letter-spacing:0.07px;word-spacing:0.12px;}
#tr_182{left:35px;bottom:482px;letter-spacing:0.12px;word-spacing:0.06px;}
#ts_182{left:35px;bottom:459px;letter-spacing:0.13px;word-spacing:0.06px;}
#tt_182{left:35px;bottom:436px;letter-spacing:0.14px;word-spacing:0.05px;}
#tu_182{left:35px;bottom:413px;letter-spacing:0.11px;word-spacing:0.07px;}
#tv_182{left:35px;bottom:390px;letter-spacing:0.22px;}
#tw_182{left:88px;bottom:397px;}
#tx_182{left:133px;bottom:390px;letter-spacing:0.08px;word-spacing:0.1px;}
#ty_182{left:35px;bottom:351px;letter-spacing:-0.25px;word-spacing:0.67px;}
#tz_182{left:35px;bottom:327px;letter-spacing:0.12px;word-spacing:0.07px;}
#t10_182{left:35px;bottom:304px;letter-spacing:-0.03px;word-spacing:0.22px;}
#t11_182{left:422px;bottom:312px;letter-spacing:-0.01px;}
#t12_182{left:445px;bottom:304px;letter-spacing:0.08px;word-spacing:0.11px;}
#t13_182{left:35px;bottom:281px;letter-spacing:0.06px;word-spacing:-0.47px;}
#t14_182{left:35px;bottom:258px;letter-spacing:0.04px;word-spacing:0.14px;}
#t15_182{left:462px;bottom:265px;letter-spacing:0.12px;}
#t16_182{left:529px;bottom:258px;letter-spacing:0.44px;}
#t17_182{left:35px;bottom:234px;letter-spacing:0.03px;word-spacing:0.15px;}
#t18_182{left:35px;bottom:211px;letter-spacing:0.17px;word-spacing:0.01px;}
#t19_182{left:35px;bottom:188px;letter-spacing:0.12px;word-spacing:-0.65px;}
#t1a_182{left:35px;bottom:165px;letter-spacing:0.18px;word-spacing:0.01px;}
#t1b_182{left:391px;bottom:172px;letter-spacing:0.1px;}
#t1c_182{left:436px;bottom:165px;letter-spacing:0.02px;word-spacing:0.16px;}
#t1d_182{left:35px;bottom:141px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1e_182{left:35px;bottom:118px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1f_182{left:35px;bottom:95px;letter-spacing:0.19px;word-spacing:-0.1px;}
#t1g_182{left:35px;bottom:72px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1h_182{left:618px;bottom:777px;letter-spacing:0.1px;word-spacing:0.08px;}
#t1i_182{left:618px;bottom:754px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1j_182{left:901px;bottom:761px;letter-spacing:-0.01px;}
#t1k_182{left:924px;bottom:754px;letter-spacing:-0.03px;word-spacing:0.22px;}
#t1l_182{left:618px;bottom:731px;letter-spacing:0.15px;word-spacing:-0.85px;}
#t1m_182{left:991px;bottom:731px;}
#t1n_182{left:1007px;bottom:731px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1o_182{left:618px;bottom:707px;letter-spacing:0.21px;word-spacing:-0.03px;}
#t1p_182{left:816px;bottom:707px;}
#t1q_182{left:832px;bottom:707px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1r_182{left:618px;bottom:684px;letter-spacing:0.16px;word-spacing:0.02px;}
#t1s_182{left:618px;bottom:661px;letter-spacing:0.06px;word-spacing:-0.86px;}
#t1t_182{left:618px;bottom:638px;letter-spacing:0.12px;word-spacing:-0.46px;}
#t1u_182{left:618px;bottom:614px;letter-spacing:0.12px;word-spacing:-0.38px;}
#t1v_182{left:618px;bottom:591px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1w_182{left:618px;bottom:568px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1x_182{left:618px;bottom:545px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1y_182{left:618px;bottom:506px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1z_182{left:618px;bottom:482px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t20_182{left:618px;bottom:459px;letter-spacing:0.04px;word-spacing:0.15px;}
#t21_182{left:618px;bottom:436px;word-spacing:0.19px;}
#t22_182{left:957px;bottom:444px;letter-spacing:0.1px;}
#t23_182{left:1002px;bottom:436px;letter-spacing:0.13px;word-spacing:0.06px;}
#t24_182{left:618px;bottom:413px;letter-spacing:0.05px;word-spacing:-0.95px;}
#t25_182{left:618px;bottom:390px;letter-spacing:0.12px;word-spacing:0.07px;}
#t26_182{left:618px;bottom:366px;letter-spacing:0.18px;word-spacing:-0.27px;}
#t27_182{left:618px;bottom:343px;letter-spacing:0.15px;word-spacing:0.04px;}
#t28_182{left:618px;bottom:320px;letter-spacing:-0.03px;word-spacing:0.22px;}
#t29_182{left:898px;bottom:327px;letter-spacing:0.1px;}
#t2a_182{left:939px;bottom:320px;letter-spacing:0.1px;word-spacing:0.08px;}
#t2b_182{left:1054px;bottom:327px;letter-spacing:0.1px;}
#t2c_182{left:1094px;bottom:320px;}
#t2d_182{left:618px;bottom:297px;letter-spacing:-0.01px;}
#t2e_182{left:798px;bottom:304px;letter-spacing:-0.01px;}
#t2f_182{left:816px;bottom:297px;letter-spacing:0.02px;word-spacing:0.16px;}
#t2g_182{left:1017px;bottom:304px;letter-spacing:-0.01px;}
#t2h_182{left:1040px;bottom:297px;letter-spacing:0.19px;word-spacing:-0.01px;}
#t2i_182{left:618px;bottom:273px;letter-spacing:0.09px;word-spacing:-1.13px;}
#t2j_182{left:618px;bottom:250px;letter-spacing:-0.07px;word-spacing:-0.06px;}
#t2k_182{left:902px;bottom:258px;letter-spacing:-0.01px;}
#t2l_182{left:925px;bottom:250px;letter-spacing:0.01px;word-spacing:0.18px;}
#t2m_182{left:618px;bottom:227px;letter-spacing:0.08px;word-spacing:0.1px;}
#t2n_182{left:961px;bottom:227px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t2o_182{left:618px;bottom:204px;letter-spacing:0.23px;word-spacing:-0.04px;}
#t2p_182{left:820px;bottom:204px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2q_182{left:618px;bottom:181px;letter-spacing:0.09px;}
#t2r_182{left:693px;bottom:188px;letter-spacing:0.06px;}
#t2s_182{left:618px;bottom:140px;letter-spacing:0.04px;word-spacing:0.14px;}
#t2t_182{left:618px;bottom:117px;letter-spacing:0.18px;word-spacing:0.01px;}
#t2u_182{left:618px;bottom:94px;letter-spacing:-0.01px;word-spacing:0.69px;}
#t2v_182{left:618px;bottom:71px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2w_182{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_182{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_182{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_182{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_182{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_182{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_182{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s6_182{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s7_182{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s8_182{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts182" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg182Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg182" style="-webkit-user-select: none;"><object width="1210" height="935" data="182/182.svg" type="image/svg+xml" id="pdf182" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_182" class="t s0_182">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_182" class="t s1_182">© </span>
<span id="t3_182" class="t s0_182">(NCCN </span>
<span id="t4_182" class="t s1_182">© </span>
<span id="t5_182" class="t s0_182">), All rights reserved. NCCN Guidelines </span>
<span id="t6_182" class="t s1_182">® </span>
<span id="t7_182" class="t s0_182">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_182" class="t s2_182">NCCN Guidelines Version 4.2024 </span>
<span id="t9_182" class="t s2_182">Head and Neck Cancers </span>
<span id="ta_182" class="t s3_182">MS-41 </span>
<span id="tb_182" class="t s4_182">equally reasonable to use regimens established in other non–EBV-related </span>
<span id="tc_182" class="t s4_182">SCCHN sites, such as TPF. See </span><span id="td_182" class="t s5_182">Systemic Therapy for Locally Advanced </span>
<span id="te_182" class="t s5_182">Squamous Cell Carcinoma of the Head and Neck</span><span id="tf_182" class="t s4_182">, above in this </span>
<span id="tg_182" class="t s4_182">Discussion regarding the role of induction for non-NPC SCCHN. </span>
<span id="th_182" class="t s4_182">The panel recommends concurrent systemic therapy/RT (cisplatin) with </span>
<span id="ti_182" class="t s4_182">either induction or adjuvant chemotherapy for locoregionally advanced </span>
<span id="tj_182" class="t s4_182">NPC, favoring induction over adjuvant in the clinical scenarios discussed </span>
<span id="tk_182" class="t s4_182">above. Concurrent cisplatin with RT is recommended for all patients who </span>
<span id="tl_182" class="t s4_182">do not have a contraindication to the drug, because the vast majority of </span>
<span id="tm_182" class="t s4_182">randomized trials support the use of cisplatin in this setting. </span>
<span id="tn_182" class="t s6_182">318,500 </span>
<span id="to_182" class="t s4_182">If using </span>
<span id="tp_182" class="t s4_182">adjuvant chemotherapy, the preferred option remains cisplatin/5-FU. Use </span>
<span id="tq_182" class="t s4_182">of metronomic capecitabine as an adjuvant chemotherapy option for </span>
<span id="tr_182" class="t s4_182">treatment of stage III–IVa disease (excluding T3–4, N0 and T3, N1) is </span>
<span id="ts_182" class="t s4_182">supported by two randomized phase III trials (discussed above). The </span>
<span id="tt_182" class="t s4_182">substitution of carboplatin or other platinum substitutes for cisplatin in </span>
<span id="tu_182" class="t s4_182">induction, concurrent, and adjuvant regimens, while studied to some </span>
<span id="tv_182" class="t s4_182">extent, </span>
<span id="tw_182" class="t s6_182">527-529 </span>
<span id="tx_182" class="t s4_182">should be limited to cisplatin-ineligible patients. </span>
<span id="ty_182" class="t s7_182">Metastatic Disease </span>
<span id="tz_182" class="t s4_182">Population-based data appear to support the role of earlier RT in the </span>
<span id="t10_182" class="t s4_182">management of metastatic nasopharyngeal cancer, </span>
<span id="t11_182" class="t s6_182">530 </span>
<span id="t12_182" class="t s4_182">but treatment </span>
<span id="t13_182" class="t s4_182">ultimately depends on whether the disease is localized or widespread and </span>
<span id="t14_182" class="t s4_182">if it is symptomatic or posing a clinical risk to the patient. </span>
<span id="t15_182" class="t s6_182">318,500,527 </span>
<span id="t16_182" class="t s4_182">For </span>
<span id="t17_182" class="t s4_182">patients with oligometastatic disease, potentially curative therapy (ie, RT </span>
<span id="t18_182" class="t s4_182">alone or surgery) is indicated if the patient is fit (ECOG 0–1); this </span>
<span id="t19_182" class="t s4_182">locoregionally-focused approach is often used following robust anti-tumor </span>
<span id="t1a_182" class="t s4_182">effects observed with systemic chemotherapy. </span>
<span id="t1b_182" class="t s6_182">531,532 </span>
<span id="t1c_182" class="t s4_182">In a multicenter </span>
<span id="t1d_182" class="t s4_182">randomized phase III trial, patients (N = 126) with de novo metastatic </span>
<span id="t1e_182" class="t s4_182">nasopharyngeal cancer who achieved a complete response or partial </span>
<span id="t1f_182" class="t s4_182">response after the first 3 cycles of cisplatin/5-FU and with good PS were </span>
<span id="t1g_182" class="t s4_182">randomized to receive or not receive consolidative locoregional IMRT </span>
<span id="t1h_182" class="t s4_182">directed at the primary and nodal gross disease to total doses of 70 Gy </span>
<span id="t1i_182" class="t s4_182">after completion of 6 planned cycles. </span>
<span id="t1j_182" class="t s6_182">533 </span>
<span id="t1k_182" class="t s4_182">The IMRT arm was associated </span>
<span id="t1l_182" class="t s4_182">with improved OS (HR, 0.42; 95% CI, 0.23–0.77; </span><span id="t1m_182" class="t s5_182">P </span><span id="t1n_182" class="t s4_182">= .004) and PFS (HR, </span>
<span id="t1o_182" class="t s4_182">0.36; 95% CI, 0.23–0.57; </span><span id="t1p_182" class="t s5_182">P </span><span id="t1q_182" class="t s4_182">&lt; .001) compared to chemotherapy alone. </span>
<span id="t1r_182" class="t s4_182">Based on the results of this study, RT at a definitive dose level to the </span>
<span id="t1s_182" class="t s4_182">primary site and involved regional nodes is recommended for patients with </span>
<span id="t1t_182" class="t s4_182">oligometastatic NPC if complete response (or near complete response) is </span>
<span id="t1u_182" class="t s4_182">achieved with systemic therapy. However, it should be noted that the role </span>
<span id="t1v_182" class="t s4_182">of consolidative radiation has yet to be completely established in the </span>
<span id="t1w_182" class="t s4_182">current era where immunochemotherapy has now become the </span>
<span id="t1x_182" class="t s4_182">recommended initial treatment in the first-line metastatic setting. </span>
<span id="t1y_182" class="t s4_182">Gemcitabine plus cisplatin (GC) with or without toripalimab-tpzi is the </span>
<span id="t1z_182" class="t s4_182">preferred combination systemic therapy regimen for first-line therapy for </span>
<span id="t20_182" class="t s4_182">patients with metastatic NPC based on category 1 level evidence </span>
<span id="t21_182" class="t s4_182">demonstrating a survival advantage over PF. </span>
<span id="t22_182" class="t s6_182">534,535 </span>
<span id="t23_182" class="t s4_182">See discussion of </span>
<span id="t24_182" class="t s4_182">immunotherapy below. Because the data for GC demonstrating superiority </span>
<span id="t25_182" class="t s4_182">to PF comes from an era when GC was not typically used for induction, </span>
<span id="t26_182" class="t s4_182">the superiority of GC over PF in patients who have had prior exposure to </span>
<span id="t27_182" class="t s4_182">GC is unknown. Other combination regimens for these patients include </span>
<span id="t28_182" class="t s4_182">cisplatin or carboplatin, plus a taxane </span>
<span id="t29_182" class="t s6_182">536,537 </span>
<span id="t2a_182" class="t s4_182">; cisplatin/5-FU </span>
<span id="t2b_182" class="t s6_182">537,538 </span>
<span id="t2c_182" class="t s4_182">; </span>
<span id="t2d_182" class="t s4_182">gemcitabine/carboplatin </span>
<span id="t2e_182" class="t s6_182">539 </span>
<span id="t2f_182" class="t s4_182">; or carboplatin/cetuximab. </span>
<span id="t2g_182" class="t s6_182">539 </span>
<span id="t2h_182" class="t s4_182">Results from a </span>
<span id="t2i_182" class="t s4_182">comparison of five different cisplatin-based regimens for NPC showed that </span>
<span id="t2j_182" class="t s4_182">all had substantial anti-cancer activity. </span>
<span id="t2k_182" class="t s6_182">540 </span>
<span id="t2l_182" class="t s4_182">Active and more commonly used </span>
<span id="t2m_182" class="t s4_182">single agents are listed in the algorithm (see </span><span id="t2n_182" class="t s5_182">Systemic Therapy for </span>
<span id="t2o_182" class="t s5_182">Nasopharyngeal Cancers </span><span id="t2p_182" class="t s4_182">in the NCCN Guidelines for Head and Neck </span>
<span id="t2q_182" class="t s4_182">Cancers). </span>
<span id="t2r_182" class="t s6_182">538,541-552 </span>
<span id="t2s_182" class="t s4_182">Toripalimab-tpzi, in combination with GC, is a category 1 preferred option </span>
<span id="t2t_182" class="t s4_182">in the NCCN Guidelines for first-line treatment of recurrent or metastatic </span>
<span id="t2u_182" class="t s4_182">NPC. Toripalimab, in combination with GC, was evaluated as a first-line </span>
<span id="t2v_182" class="t s4_182">therapy option for recurrent or metastatic NPC in the randomized phase </span>
<span id="t2w_182" class="t s8_182">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
